NewsEuropeMaltese Medical Cannabis To Boost Exports

Maltese Medical Cannabis To Boost Exports

-

THE Maltese approach to cannabis is set to see its total value of exports increase by 30%.

Malta decriminalised cannabis in 2013, and legalised medical cannabis in March, 2018 and has since made significant strides in becoming a leading player in the emerging European market.

In an interview with Health Europa in 2019 Marion Zammit of Malta Enterprise confirmed over 20 projects had been approved.

She said these included Canadian, Australian and US companies. In June, last year Aphria’s Malta subsidiary, ASG Pharma, received an import license from The Malta Medicines Authority.

Malta Enterprise has granted Canadian firm Aurora approval for a seed-to-pharma operation in partnership with local firm Cherubino.

Australian firm MGC Pharmaceuticals signed a deal with the Maltese government which will see it create an € 11m medical cannabis manufacturing plant.

Whilst Toronto firms MPXI and Supreme and US firm Columbia Care, are also amongst the 20 approved projects. 

Ms Zammit went on to say that once all approved projects are in operational it ‘will supplement exports by an additional 30%’, adding: “We are creating a new sub-niche in the manufacturing sector and this in turn will make our economy more robust.”

Malta, a small Mediterranean island with a population of less than half a million, has a strong advanced manufacturing and pharmaceutical base.

It promotes itself as being in an ‘ideal geographic location capable of  bridging continents’, with English being the language of choice for business. 

MGC Pharmaceuticals founder and director Nativ Segev said its move allows it to be a ‘part of Malta’s drive to become a beacon in Europe for the growth and development of this industry’. 

Economy Minister Chris Cardona said that as the first country in the EU to provide a regulatory framework for medical cannabis ‘it has been able to attract the best investment to our country, with the sector already contributing to economic growth’.

Peter
Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Tilray’s Medical Cannabis Product Now Available And Reimbursed Under Ireland’s Medical Cannabis Access Program

PRESS RELEASE TILRAY Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and...

Grow Group, Kanabo, MGC Pharma & Celadon Pharma All Report Growing Revenues, But Continue To Post Losses

AMID the economic chaos that dominated the headlines over the past week, nearly half-a-dozen UK-based or UK-listed cannabis companies...

MGC Pharma Announces Appointment Of UK Advisor And New COO/Deputy CEO

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development...

Sanity Group’s Record Funding Round Led By BAT Could Bring More Big-Tobacco Capital To Cannabis, But Concerns Remain Over Conflicts Of Interest

LAST week Berlin-based cannabis operator Sanity Group closed Europe’s largest ever cannabis investment round worth €37.6m, bringing its total...

European Cannabis Stocks Review: £22m Wiped From LSE-Listed Cannabis Stocks Amid Market Chaos

FOLLOWING a few weeks of relative positivity for many of the stocks listed on the London Stock Exchange (LSE),...

German SPD Representatives Confident A Solution To International Legal Hurdles Will Be Found

EARLIER this month news broke that recent analysis conducted by the Bundestag's scientific service suggested the creation of a...

Must read

You might also likeRELATED
Recommended to you